INSIGHTS ON DRUG DEVELOPMENT

• Navigating Nitrosamine Impurities In Pharmaceutical Drug Development

  Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.

• Quantification Of Semaglutide With A Reliable Analytical Method

  Explore a validated LC-MS/MS method for precise Semaglutide quantification in plasma, which features enhanced sensitivity, peak definition, and reproducibility using innovative technologies.

• The Rise Of Complex OSD Generics: Understanding Development Challenges

  Understanding the potential pitfalls and partnering with the right experts can make all the difference in overcoming the complexities of complex generic OSD development.

• The Complete Flow Cytometry Guide

  This guide covers the fundamentals of flow cytometry, aiming to help you better understand how it works, when it is most valuable, and how to conduct an experiment.

• Detect Low-Abundance GLP-1 Impurities With Greater Sensitivity

  8/24/2026

  Low-level impurities can be difficult to resolve using conventional approaches. Discover how a Charged Surface 2.3 µm superficially porous Phenyl-Hexyl column enhances reversed-phase LC-MS analysis.

• An Integrated Analytical Approach To Lipase Risk Management In Biologics Development

  9/8/2026

  Conventional HCP testing cannot confirm whether residual lipases remain enzymatically active. Here, the authors examine why functional activity data are essential for managing polysorbate-related stability risk in biologics development.

• Predicting Drug-Loading Limits In Tablet Formulations

  7/15/2026

  Learn how predictive percolation modeling identified critical drug-loading limits of ~20% for crystalline API and ~15% for SDD forms, cutting tablet formulation trial-and-error significantly.

• Understanding Adeno-Associated Virus Vector Impurities

  11/13/2025

  AAV vectors hold promise for gene therapy, but removing product-related impurities remains a challenge. Learn how cell line development and process optimization are advancing rAAV production.

• Target Product Profiles And Phase 1 Clinical Plans: Laying The Groundwork For Success

  2/26/2025

  By integrating scientific rigor, regulatory foresight, and market awareness into early-stage planning, companies can leverage a robust TPP to optimize decision-making and development.